Ascendis Pharma A (ASND) Non-Current Deferred Tax Liability (2023 - 2025)

Ascendis Pharma A (ASND) has 3 years of Non-Current Deferred Tax Liability data on file, last reported at $11.2 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Deferred Tax Liability rose 44.43% year-over-year to $11.2 million; the trailing twelve-month figure through Dec 2025 stood at $11.2 million (up 44.43% YoY), and the FY2025 full-year result was $11.2 million, up 42.59% from the prior year.
• Non-Current Deferred Tax Liability slipped to $11.2 million in Q4 2025, from $12.0 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $12.0 million in Q3 2025 to a low of $6.3 million in Q4 2023.
• A 3-year average of $9.1 million and a median of $8.2 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
• Peak annual rise in Non-Current Deferred Tax Liability reached 44.43% in 2025, while the deepest fall reached 5.68% in 2025.
• Tracing ASND's Non-Current Deferred Tax Liability over 3 years: stood at $6.3 million in 2023, then advanced by 23.64% to $7.8 million in 2024, then surged by 44.43% to $11.2 million in 2025.
• Business Quant data shows ASND's Non-Current Deferred Tax Liability at $11.2 million in Q4 2025, $12.0 million in Q3 2025, and $10.9 million in Q2 2025.